利用腫瘤球體及晶片形態模型來研究抗癌胜肽藥物與肺癌細胞之作用

Interaction of Anticancer Peptide with Lung Cancer Cells Studied by Tumor Spheroid and Chip Pattern Models

潘韻如 ； 陳惠民

《國家奈米元件實驗室奈米通訊》 17卷3期 (2010/09) Pp. 11-15

https://doi.org/10.29913/NDLC.201009.0003

摘要

肺癌死亡率無論在全球或台灣都居高不下，診斷確定時，又通常屬於晚期，其治癒率或五年存活率都偏低，再加上臨床的抗癌藥物其副作用大且多，對於癌症病患來說，其生活品質就大大地被降低。為此，我們發展出一個人體可接受、較無副作用之抗癌胜肽(C B1a)，其在平面式(2D)之培養皿中已發現對肺癌細胞有明顯的毒殺作用。為求模擬癌細胞在人體的狀態，在本篇文章中，我們進一步運用立體(3D)的腫瘤球體模式來測試C B1a。實驗結果發現，C B1a對腫瘤球體成長之癌細胞亦有毒殺效果。因此C B1a應具有發展成臨床用藥之潛力。未來將配合晶片的特殊設計，以便提供更精確的藥物與細胞作用之觀察，並期能建立以晶片形態為基礎之新藥物測試模型。

關鍵字

肺癌 ； 腫瘤球體 ； 抗癌胜肽 ； 晶片形態

並列摘要

Mortality of lung cancer in Taiwan or other countries has always been listed in top ranking. This is because lung cancer is hard to be successfully detected in the early stage (s) and usually leveled with incurable situation when it is found. Also, there are many side effects by taking the current anticancer agents. Based on the concerns above, a less side-effects and non-harmful custom anti-cancer peptide (CB1a) composed by 35 amino acids was created. In this report, a mimic tumor model in water drop (3D spheroid tumor) was established and used for the study of the interaction with peptide. The results show that the peptide drug has cytotoxicity effect on cancer cells either in monolayer solution (in vitro) or in spheroid tumor (in semi-vivo). This indicates that our custom peptide can be developed as a clinical drug in the future. Further tasks will be done by determining the cytotoxic effect more precisely via chip pattern.

並列關鍵字

Lung Cancer ； Tumor Spheroid ； Anti-Cancer Peptide ； Chip Pattern